Genmab A (GMAB) Other Non-Current Assets (2025)
Genmab A's (GMAB) quarterly Other Non-Current Assets came in at $14.0 million in Q4 2025, up 55.56% quarter-over-quarter from $9.0 million in Q3 2025.
Powered by 
Analysis
Genmab A (GMAB) Other Non-Current Assets (2025) Analysis & Trends
Genmab A (GMAB) has reported Other Non-Current Assets for 1 consecutive years, with $14.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets changed N/A year-over-year to $14.0 million; the trailing twelve-month figure through Dec 2025 stood at $14.0 million (changed N/A YoY), and the FY2025 full-year result was $14.0 million, changed N/A from the prior year.
- Other Non-Current Assets advanced to $14.0 million in Q4 2025 per GMAB's latest filing, from $9.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $14.0 million in Q4 2025 and bottomed at $9.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 618.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 124.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | - |